{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:31:42Z","timestamp":1783960302982,"version":"3.55.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:00:00Z","timestamp":1550534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00083","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T23:54:49Z","timestamp":1550534089000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications"],"prefix":"10.3389","volume":"10","author":[{"given":"Marin","family":"Veldic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed T.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caren J.","family":"Blacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Geske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Biernacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin L.","family":"Borreggine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel L.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Vande Voort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Croarkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid A.","family":"Hoberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Alarcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Keeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balwinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William V.","family":"Bobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jad.2018.12.021","article-title":"Pharmacokinetic-pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram \/ escitalopram treatment failure.","volume":"246","author":"Ahmed","year":"2018","journal-title":"J. Affect Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/0269881107088441","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 british association for psychopharmacology guidelines.","volume":"22","author":"Anderson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1126\/science.1083968","article-title":"Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.","volume":"301","author":"Caspi","year":"2003","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4088\/JCP.v60n0302","article-title":"The texas medication algorithm project: report of the texas consensus conference panel on medication treatment of major depressive disorder.","volume":"60","author":"Crismon","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/gm546","article-title":"Genomic insights into the overlap between psychiatric disorders: implications for research and clinical practice.","volume":"6","author":"Doherty","year":"2014","journal-title":"Genome Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/phar.1398","article-title":"Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.","volume":"34","author":"Drozda","year":"2014","journal-title":"Pharmacotherapy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0749-3797(98)00017-8","article-title":"Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults.","volume":"14","author":"Felitti","year":"1998","journal-title":"Am. J. Prev. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bdi.12423","article-title":"The prevalence and burden of bipolar disorder: findings from the global burden of disease study 2013.","volume":"18","author":"Ferrari","year":"2016","journal-title":"Bipolar Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMcp1000402","article-title":"Bipolar disorder \u2014 a focus on depression.","volume":"364","author":"Frye","year":"2011","journal-title":"New Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4088\/JCP.14m09127","article-title":"Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania.","volume":"76","author":"Frye","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s004390050624","article-title":"Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects.","volume":"101","author":"Gelernter","year":"1997","journal-title":"Hum. Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00702-014-1273-4","article-title":"Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors.","volume":"122","author":"Gressier","year":"2015","journal-title":"J. Neural. Transm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/FPC.0b013e3283649b9a","article-title":"Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting.","volume":"23","author":"Hall-Flavin","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.99","article-title":"Using a pharmacogenomic algorithm to guide the treatment of depression.","volume":"2","author":"Hall-Flavin","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors.","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1086\/503850","article-title":"Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.","volume":"78","author":"Hu","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"B18","first-page":"46","article-title":"The clinical use of pharmacogenomic testing in treatment-resistant depression.","volume":"17","author":"Kung","year":"2010","journal-title":"Prim. Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/ng.2711","article-title":"Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs.","volume":"45","author":"Lee","year":"2013","journal-title":"Nat. Genet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0140-6736(09)60072-6","article-title":"Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study.","volume":"373","author":"Lichtenstein","year":"2009","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/archpsyc.60.5.497","article-title":"The heritability of bipolar affective disorder and the genetic relationship to unipolar depression.","volume":"60","author":"McGuffin","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FPC.0b013e328340bc5a","article-title":"CYP2C19 variation and citalopram response.","volume":"21","author":"Mrazek","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/ajmg.b.30816","article-title":"SLC6A4 variation and citalopram response.","author":"Mrazek","year":"2009","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.mayocp.2016.02.023","article-title":"Pharmacokinetic pharmacogenetic prescribing guidelines for antidepressants: a template for psychiatric precision medicine.","volume":"91","author":"Nassan","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.euroneuro.2011.10.003","article-title":"Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy.","volume":"22","author":"Porcelli","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.4088\/JCP.15r10583","article-title":"Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? a systematic review of clinical trials and cost-effectiveness studies.","volume":"78","author":"Rosenblat","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jad.2018.08.056","article-title":"The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis.","volume":"241","author":"Rosenblat","year":"2018","journal-title":"J. Affect. Disord."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2011.7","article-title":"Pharmacogenomic testing and outcome among depressed patients in a tertiary care outpatient psychiatric consultation practice.","volume":"1","author":"Rundell","year":"","journal-title":"Transl. Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.psym.2010.12.023","article-title":"Pharmacogenomic testing in a tertiary care outpatient psychosomatic medicine practice.","volume":"52","author":"Rundell","year":"","journal-title":"Psychosomatics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR\u2217D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4088\/JCP.09r05385gre","article-title":"Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis.","volume":"72","author":"Sidor","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"B32","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","article-title":"Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire.","volume":"282","author":"Spitzer","year":"1999","journal-title":"JAMA"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the gad-7.","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Internal Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/gim.0b013e3182329870","article-title":"Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory.","volume":"14","author":"Strom","year":"2012","journal-title":"Genet. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1176\/appi.ajp.157.10.1552","article-title":"Genetic epidemiology of major depression: review and meta-analysis.","volume":"157","author":"Sullivan","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2217\/pgs.09.168","article-title":"Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.","volume":"11","author":"Tsai","year":"2010","journal-title":"Pharmacogenomics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the global burden of disease study 2013.","volume":"386","author":"Vos","year":"2015","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/sj.mp.4001789","article-title":"Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531.","volume":"11","author":"Wendland","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010.","volume":"382","author":"Whiteford","year":"2013","journal-title":"Lancet"},{"key":"B40","first-page":"219","article-title":"A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder.","volume":"16","author":"Winner","year":"2013","journal-title":"Discov. Med."},{"key":"B41","year":"2018","journal-title":"Depression and Other Common Mental Disorders."},{"key":"B42","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1176\/appi.ajp.2018.17111282","article-title":"Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing.","volume":"175","author":"Zeier","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/jamapsychiatry.2018.0834","article-title":"On the marketing and use of pharmacogenetic tests for psychiatric treatment.","volume":"75","author":"Zubenko","year":"2018","journal-title":"JAMA Psychiatry"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T23:54:52Z","timestamp":1550534092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,19]]},"references-count":43,"alternative-id":["10.3389\/fphar.2019.00083"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00083","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,19]]},"article-number":"83"}}